• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Senate confirms Dr. von Eschenbach as FDA commissioner

Article

Urologist Andrew von Eschenbach, MD, has been confirmed by the Senate as commissioner of the Food and Drug Administration.

Urologist Andrew von Eschenbach, MD, has been confirmed by the Senate as commissioner of the Food and Drug Administration. Dr. von Eschenbach has been the acting FDA commissioner since September 2005, and this action makes his position permanent.

Dr. von Eschenbach was formally nominated as commissioner in March, but his confirmation was delayed by objections from both Democratic and Republican senators over the agency’s delay of Plan B emergency contraceptives and the administration’s stance on drug reimportation.

Dr. von Eschenbach was the founding director of the Prostate Cancer Research Program at the University of Texas M.D. Anderson Cancer Center in Houston, and is the former director of the National Cancer Institute. He graduated from the Georgetown University School of Medicine and completed his residency in urologic surgery at Pennsylvania Hospital in Philadelphia, and was an instructor in urology at the University of Pennsylvania School of Medicine.

Related Videos
Samuel L. Washington III, MD, MAS, answers a question during a Zoom video interview
Human kidney cross section on scientific background | © Crystal light - stock.adobe.com
Leo Dreyfuss, MD, answers a question during a Zoom video interview
Neal Shore, MD, FACS, and Brian M. Shuch, MD, experts on kidney cancer
Neal Shore, MD, FACS, and Brian M. Shuch, MD, experts on kidney cancer
Conceptual image for prostate cancer treatment | © Dr_Microbe - stock.adobe.com
David Gilbert answers a question during a Zoom video interview
Related Content
© 2024 MJH Life Sciences

All rights reserved.